Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink - 2San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- 3These are the Fastest Italian Sports Cars
- 4The Response to Self-improvement: Embracing a Development Outlook
- 5SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Child influencers helped power a booming industry. It's time for a reckoning.
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- Pick Your #1 breakfast food
- Europe picks companies to help build Argonaut moon lander
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
